Literature DB >> 32644124

Associations between polycystic ovary syndrome and adverse obstetric and neonatal outcomes: a population study of 9.1 million births.

Ginevra Mills1, Ahmad Badeghiesh1, Eva Suarthana1, Haitham Baghlaf1, Michael H Dahan1.   

Abstract

STUDY QUESTION: Does polycystic ovary syndrome (PCOS) confer an independent risk for adverse delivery and neonatal outcomes, based on analysis of the Healthcare Cost and Utilization Project-Nationwide Inpatient Sample (HCUP-NIS) database? SUMMARY ANSWER: After controlling for all potential confounding effects, women with PCOS are at an increased risk of experiencing preterm pre-labour rupture of membranes (PPROM), pre-term delivery (PTD), placental abruption, caesarean section (C/S) delivery, chorioamnionitis and post-partum maternal infections. WHAT IS KNOWN ALREADY: PCOS may be associated with an increased risk of adverse perinatal outcomes. However, there remain significant gaps in understanding the correlation between PCOS and important delivery and neonatal complications. STUDY DESIGN, SIZE, DURATION: This is a retrospective population-based cohort study utilising data from the HCUP-NIS over 11 years from 2004 to 2014. A cohort of all deliveries between 2004 and 2014 inclusively was created. Within this group, all deliveries to women with PCOS were identified as part of the study group (n = 14 882), and the remaining deliveries were categorised as non-PCOS births and comprised the reference group (n = 9 081 906). PARTICIPANTS/MATERIALS, SETTING,
METHODS: The HCUP-NIS is the largest inpatient sample database in the USA and it is comprised of hospital inpatient stays throughout the entire country. It provides information relating to 7 million inpatient stays per year, includes ∼20% of admissions, and represents over 96% of the American population. MAIN RESULTS AND THE ROLE OF CHANCE: After adjustment for all potential confounders, women with PCOS were more likely to experience PPROM (aOR 1.48, 95% CI 1.20-1.83), PTD (aOR 1.37 95% CI 1.24-1.53) and placental abruption (aOR 1.63, 95% CI 1.30-2.05) and were more likely to deliver by C/S (aOR 1.50, 95% CI 1.40-1.61 (all P < 0.001). Women with PCOS more often developed chorioamnionitis (aOR 1.58, 95% CI 1.34-1.86, P < 0.001) and maternal infections (aOR 1.58, 95% CI 1.36-1.84 (both P < 0.001)). With the exception of multiple gestations (aOR 1.27, 95% CI 1.01-1.62, P = 0.04), there was no difference in the number of women who gave birth to small for gestational age (SGA) infants (aOR 0.97, 95% CI 0.82-1.15, P = 0.72) between the women with PCOS and the reference group. Intrauterine foetal deaths (IUFDs) were also comparable between the two groups (aOR 1.03, 95% CI 0.68-1.59, P = 0.88). However, congenital anomalies were more likely to occur in the offspring of women with PCOS (aOR 1.89, 95% CI 1.51-2.38, P < 0.001). LIMITATIONS, REASONS FOR CAUTION: This is a retrospective analysis utilising an administrative database which relies on the accuracy and consistency of the individuals coding the data. There are known limitations in how accurately hospital coding is able to capture perinatal conditions and complications, making it difficult to know with certainty that such events are accurate. WIDER IMPLICATIONS OF THE
FINDINGS: Women with PCOS are more likely to experience adverse delivery and neonatal outcomes. It is important to additionally consider the risk of all other co-existing conditions frequently encountered in PCOS women, as these risks are additive and place women with PCOS at significantly increased risk of adverse pregnancy outcomes. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was obtained for this study. The authors have no conflicts of interest to disclose.
© The Author(s) 2020. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  PCOS; neonatal outcomes; obstetric outcomes; perinatal outcomes; polycystic ovary syndrome

Mesh:

Year:  2020        PMID: 32644124     DOI: 10.1093/humrep/deaa144

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Hyperandrogenemia alters mitochondrial structure and function in the oocytes of obese mouse with polycystic ovary syndrome.

Authors:  Neil R Chappell; Beth Zhou; Pardis Hosseinzadeh; Amy Schutt; William E Gibbons; Chellakkan S Blesson
Journal:  F S Sci       Date:  2020-12-10

2.  Epidemiology, Risk Factors, and Perinatal Outcomes of Placental Abruption-Detailed Annual Data and Clinical Perspectives from Polish Tertiary Center.

Authors:  Monika Bączkowska; Katarzyna Kosińska-Kaczyńska; Magdalena Zgliczyńska; Robert Brawura-Biskupski-Samaha; Beata Rebizant; Michał Ciebiera
Journal:  Int J Environ Res Public Health       Date:  2022-04-23       Impact factor: 4.614

3.  Polycystic ovary syndrome and preterm birth-what's going on?

Authors:  Sonia L Robinson; Edwina H Yeung
Journal:  Fertil Steril       Date:  2020-11-30       Impact factor: 7.329

4.  Elevated plasma pentraxin-3 in polycystic ovary syndrome is associated with hyperandrogenism: a case-control study.

Authors:  Congcong Jin; Kexin Zou; Yue Xu; Haiyan Yang; Jiexue Pan
Journal:  BMC Endocr Disord       Date:  2021-12-03       Impact factor: 2.763

5.  Analysis of Upstream Regulators, Networks, and Pathways Associated With the Expression Patterns of Polycystic Ovary Syndrome Candidate Genes During Fetal Ovary Development.

Authors:  Rafiatu Azumah; Katja Hummitzsch; Monica D Hartanti; Justin C St John; Richard A Anderson; Raymond J Rodgers
Journal:  Front Genet       Date:  2022-02-07       Impact factor: 4.599

6.  Association of maternal polycystic ovary syndrome and diabetes with preterm birth and offspring birth size: a population-based cohort study.

Authors:  Xinxia Chen; Mika Gissler; Catharina Lavebratt
Journal:  Hum Reprod       Date:  2022-05-30       Impact factor: 6.353

Review 7.  ENDOCRINOLOGY IN PREGNANCY: Targeting metabolic health promotion to optimise maternal and offspring health.

Authors:  Niamh-Maire McLennan; Jonathan Hazlehurst; Shakila Thangaratinam; Rebecca M Reynolds
Journal:  Eur J Endocrinol       Date:  2022-04-29       Impact factor: 6.558

Review 8.  The relationship between polycystic ovary syndrome and insulin resistance from 1983 to 2022: A bibliometric analysis.

Authors:  Tong Chen; Yue Yu; Fan Jia; Peijie Luan; Xinmin Liu
Journal:  Front Public Health       Date:  2022-07-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.